Sealed Air (SEE) Q1 2025 Earnings Call May 06, 2025 10:00 AM ET Speaker0 Good day, and thank you for standing by. Welcome to the Sealed Air Q1 twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please ...

Financial Data and Key Metrics Changes - Q1 net investment income per share was $0.50, representing an annualized yield on book value of 11.3% [6] - Q1 earnings per share were $0.44, reflecting an annualized return on book value of 10% [6] - Net asset value per share was $17.64, down $0.01 from the prior quarter [7] - Total investment income for Q1 was $66.8 million, down from $73.3 million in the previous quarter [19] - Net investment income for the quarter was $32.1 million, or $0.50 per share, compared to $33.6 million, or $0.52 per share, for the prior quarter [20] Business Line Data and Key Metrics Changes - Gross originations for Q1 were $277 million, down 31% year over year [8] - 51% of total fundings were made to new portfolio companies, while 49% were to existing companies [13] - 90% of investments were made into first lien senior secured loans, with 9% in subordinated debt and 1% in equity [14] - The weighted average yield of the investment portfolio at amortized cost and fair value was 11.5% [16] Market Data and Key Metrics Changes - Middle market direct lending volumes saw compression amid high competition, particularly in the upper and larger ends of the market [8] - Investments on non-accrual represented 1.4% of the total investment portfolio at amortized cost and fair value as of March 31 [10][17] Company Strategy and Development Direction - The company remains focused on being disciplined capital providers, favoring middle market companies and maintaining strong lender controls [8] - The investment strategy emphasizes high free cash flow businesses, domestic manufacturing, and industries such as software, healthcare, and business services [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating potential liquidity and volatility challenges ahead, leveraging their experience across multiple market cycles [24] - The company is focused on managing the portfolio prudently while delivering attractive returns for shareholders [24] Other Important Information - The Board declared a second quarter dividend of $0.42 per share, with an additional dividend of $0.03 per share [7] - The company has approximately $823 million in total available liquidity, including $699 million of undrawn capacity on its revolving credit facility [23] Q&A Session Summary Question: On the later fundings and lower interest income - Management acknowledged that some fundings were backdated in the quarter but emphasized stable earnings yield at around 11.5% [27][29] Question: Regarding realized losses and specific investments - Management discussed two non-accrual investments that were exited, with successful recoveries achieved through restructuring efforts [35][37] Question: On the ATM and stock buybacks - Management indicated that the ATM program is opportunistic and dependent on market conditions, with stock buybacks evaluated against investment opportunities [44][45] Question: Dividend coverage and SOFR curve - Management projected no immediate need to revisit the current dividend policy, citing strong spillover income [46] Question: Incentive fee stabilization - Management expects stabilization of the incentive fee from the second quarter onwards, accounting for nuances in the look-back mechanism [50]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $776 million, representing a 19% decline year over year, with approximately 15% attributed to lower core revenues and 4% due to the divestiture of the Towanda operations [11][12] - Adjusted EBITDA for the quarter was $22 million, a decrease of $47 million compared to the prior year, resulting in an adjusted EBITDA margin of 2.8% [12][15] - Free cash flow was a use of $125 million in Q1, compared to a $46 million use in Q1 2024, primarily driven by lower EBITDA and unfavorable working capital dynamics [13][14] - The net debt leverage ratio increased to 4.6 times, exceeding the targeted range of 2 to 2.5 times [14] Business Line Data and Key Metrics Changes - North America segment reported revenue of $531 million for Q1, a 22% decline year over year, with core revenues down 17% primarily due to lower volume [16] - Adjusted EBITDA for North America declined to $16 million from $61 million in the same quarter last year [16] - Europe segment revenue was $245 million, down 12% year over year, driven almost entirely by lower volume, with adjusted EBITDA at $11 million, a decline of $4 million from the prior year [17] Market Data and Key Metrics Changes - Both North America and Europe segments experienced double-digit volume declines during the quarter [8] - The company faced ongoing product mix challenges, although the mix has stabilized compared to prior quarters [14][15] - Tariffs are expected to have an annualized impact of approximately $55 million, with about $30 million anticipated to affect 2025 results [18] Company Strategy and Development Direction - The company is focused on enhancing production capabilities, optimizing manufacturing and distribution networks, and investing in automation to drive efficiency [22][27][28] - The strategic priorities include reestablishing strong partnerships with customers, optimizing operational footprint, and investing in automation to reduce costs [27][28] - The company anticipates achieving approximately $100 million in ongoing transformation benefits and $50 million from short-term actions in 2025 [26] Management's Comments on Operating Environment and Future Outlook - The management expressed concerns about the challenging macroeconomic environment, with elevated interest rates and declining consumer confidence impacting new home construction [21] - The likelihood of a global recession is estimated at approximately 50%, which is affecting repair and remodel activity [21] - Despite the challenges, the management remains focused on cash flow maintenance and generation, with expectations for Q2 adjusted EBITDA to be slightly above Q1 levels [25] Other Important Information - The company is withdrawing its full-year guidance due to significant short-term volatility and ongoing market uncertainties [9] - The management has made difficult decisions to reduce headcount and align operations with current order rates [10][24] Q&A Session Summary Question: Confidence in passing along tariff impacts to customers - Management is in constant negotiation with key customers and believes they can pass through the $30 million tariff impact, while also optimizing their cost structure [33][35] Question: Expectations for Q2 EBITDA - Management expects a seasonal uptick in Q2, but it will be muted compared to historical trends, with sales tracking down roughly 19% [37][38] Question: Managing liquidity risk and balance sheet improvement - The company has ample liquidity and is evaluating options like sale-leaseback or asset sales to strengthen the balance sheet [51][54] Question: Market share opportunities as a U.S.-based producer - Management sees opportunities to regain market share due to tariff impacts on imports, particularly in fiberglass doors [60][62] Question: Progress on standardizing build specifications - Management is making progress on optimizing cost to serve and reducing product complexity, which will aid in future footprint consolidation [88][89] Question: New business wins with builder customers - Management is ahead of expectations for gaining new business, but the materialization of sales will take time due to the cyclical nature of the business [90][92]

Avanos Medical (AVNS) Q1 2025 Earnings Call May 06, 2025 09:00 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to the Avanus Medical Avanus First Quarter twenty twenty five Earnings Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call, This call is being recorded on Tuesday, 05/06/2025. I would now like to turn the conference over to Scott Gullivan. Please go ahead. Speaker1 Good morni ...

First Quarter 2025 Earnings Presentation 1 Legal disclaimer This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements contained in this present ...

Financial Data and Key Metrics Changes - The company reported organic sales growth of 2% in the quarter, with adjusted EBITDA growing by 4% excluding foreign exchange impacts [6][14] - Adjusted EBITDA margins expanded by 20 basis points to 17.5%, despite strong comparisons from the previous year [7] - Adjusted EPS was $0.76, representing a 4% growth when excluding unfavorable foreign exchange impacts [7][14] Business Line Data and Key Metrics Changes - The Color, Additives, and Ink segment saw organic sales growth of 3% and adjusted EBITDA growth of 7% [14] - The Specialty Engineered Materials segment's organic sales were flat year-over-year, with adjusted EBITDA declining by 4% [15] - The healthcare segment experienced double-digit growth, driven by demand in medical devices and supplies [15][16] Market Data and Key Metrics Changes - Organic sales in the U.S. and Canada declined by 3%, primarily due to weak demand in consumer and transportation markets [8] - EMEA region grew by 2%, marking the fourth consecutive quarter of organic growth [8] - Asia's organic sales increased by 9%, with growth across most end markets, particularly transportation [9] - Latin America outpaced market growth with a 17% increase in organic sales, marking the fourth consecutive quarter of double-digit growth [9] Company Strategy and Development Direction - The company is focused on cost control and productivity, expecting approximately $30 million in savings from initiatives in 2025 [11] - There is a strategic emphasis on maximizing cash flow and reducing debt by $100 million to $200 million this year [12][22] - The company aims to prioritize investments in growth vectors, particularly in healthcare and defense, which are expected to outperform the broader market [13][20] Management's Comments on Operating Environment and Future Outlook - Management noted that evolving trade policies have led to uncertainty impacting demand in select markets, particularly in the U.S. [7][19] - For Q2, the company expects adjusted EPS of $0.79, representing a 4% growth over the prior year [20] - The full-year guidance for adjusted EBITDA remains unchanged at $540 million to $570 million, with adjusted EPS guidance of $2.70 to $2.94 [22] Other Important Information - The company expects minimal direct impact from tariffs, as most raw materials are sourced and manufactured locally [12][18] - There is a focus on innovation and reformulation to mitigate tariff impacts and enhance customer offerings [53][54] Q&A Session Summary Question: Defense business expectations for the rest of the year - Management expects double-digit growth in the first half and high single-digit growth for the full year in the defense sector, despite a 5% decline in Q1 [26][27] Question: Transportation market outlook - Transportation is expected to see low negative mid-single-digit growth in the first half, aligning with build rate drops, but a potential recovery in the second half is anticipated [28][29] Question: Consumer market weakness - The consumer market showed double-digit declines in the U.S. and Canada, with expectations for continued weakness in Q2 [32][34] Question: Share gains in EMEA - Strong performance in healthcare, consumer, and defense markets contributed to share gains in EMEA, with notable wins in energy infrastructure [35] Question: Packaging segment performance - The packaging segment is driven by strong demand in personal care and beverages, with double-digit growth in personal care applications [39][40] Question: Raw material trends and inflation - The company expects 1% to 2% inflation for the full year, with specific raw materials showing varied trends [84][85] Question: Cash flow and incentive payouts - The cash flow statement reflects a $53 million use of cash related to incentive accruals, primarily from Q1 payouts [80][81]

Waters (WAT) Q1 2025 Earnings Call May 06, 2025 08:00 AM ET Speaker0 Good morning. Call is being recorded. If you have any objections, please disconnect at this time. It is now my pleasure to turn the call over to mister Caspar Tudor, head of investor relations. Please go ahead, sir. Speaker1 Thank you, Leila, and good morning, everyone. Welcome to Walters Corporation's first quarter earnings call. Joining me today are doctor Udit Batra, our president and chief executive officer and Amol Chawwal, our senior ...

5 May 2025 | 5:00AM EDT Americas Transportation: Introducing the US Tariff Impact Tracker – High Frequency Trends Plus Our Trade Scenarios Analysis for 2025 US Tariff Impact Tracker – What We Plan to Disseminate Weekly: We are introducing a series of high frequency data to help assess the ongoing impact of Tariffs on Global Supply Chains and the accompanying ramifications to the flow of freight (e.g., expected ships leaving from China to USA). While we think our data set is representative, we do plan to per ...

2 May 2025 | 10:42AM EDT US Equity Views Mid-season S&P 500 earnings update David J. Kostin +1(212)902-6781 | david.kostin@gs.com Goldman Sachs & Co. LLC Ben Snider +1(212)357-1744 | ben.snider@gs.com Goldman Sachs & Co. LLC Ryan Hammond +1(212)902-5625 | ryan.hammond@gs.com Goldman Sachs & Co. LLC Jenny Ma +1(212)357-5775 | jenny.ma@gs.com Goldman Sachs & Co. LLC Daniel Chavez +1(212)357-7657 | daniel.chavez@gs.com Goldman Sachs & Co. LLC Kartik Jayachandran +1(212)855-7744 | kartik.jayachandran@gs.com Gol ...

更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 China Healthcare Equities Takeaways on tariffs from clients and expert calls China We held joint marketing with HSBC global healthcare analysts Rajesh Kumar and Damayanti Kerai, as well an expert call, discussing the US tariff impact on China's and the global pharmaceutical supply chain. Below are our key takeaways: Tariff impact from highest to lowest: medical consumables, devices, drugs. The exact timeline and scope of tariffs remains unclear, but we expect tariffs on US pharm ...